Literature DB >> 30704681

The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management.

Alireza Atri1.   

Abstract

Alzheimer's disease (AD) care requires timely diagnosis and multidisciplinary management. Evaluation involves structured patient and caregiver history and symptom-function reviews, examination, and testing (laboratory and neuroimaging) to delineate impairment level, determine the cognitive-behavioral syndrome, and diagnose cause. Clinical biomarkers are available to aid high confidence in etiologic diagnosis. Management uses psychoeducation, shared goal setting, and patient-caregiver dyad decision making. When combined, pharmacologic and nonpharmacologic therapies mitigate symptoms and reduce clinical progression and care burden. AD biopathologic processes develop over decades before symptoms manifest; this period is increasingly targeted in research as an opportunity to best delay or prevent AD dementia.
Copyright © 2018 The Author. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Cognitive; Donepezil; Memantine; Mild cognitive impairment; Neuroimaging; Review; Treatment

Mesh:

Substances:

Year:  2019        PMID: 30704681     DOI: 10.1016/j.mcna.2018.10.009

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  80 in total

1.  Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.

Authors:  June Kaplow; Manu Vandijck; Julia Gray; Michio Kanekiyo; Els Huyck; C J Traynham; Rianne Esquivel; Anne M Fagan; Johan Luthman
Journal:  Alzheimers Dement       Date:  2020-01       Impact factor: 21.566

2.  Endocytosis-pathway polygenic scores affects the hippocampal network connectivity and individualized identification across the high-risk of Alzheimer's disease.

Authors:  Yao Zhu; Feifei Zang; Xinyi Liu; Dandan Fan; Qianqian Zhang; Qingguo Ren; Chunming Xie
Journal:  Brain Imaging Behav       Date:  2021-06       Impact factor: 3.978

3.  Multimodal measurement approach to identify individuals with mild cognitive impairment: study protocol for a cross-sectional trial.

Authors:  Bernhard Grässler; Fabian Herold; Milos Dordevic; Tariq Ali Gujar; Sabine Darius; Irina Böckelmann; Notger G Müller; Anita Hökelmann
Journal:  BMJ Open       Date:  2021-05-25       Impact factor: 2.692

4.  Dietary-challenged mice with Alzheimer-like pathology show increased energy expenditure and reduced adipocyte hypertrophy and steatosis.

Authors:  Stefanie Schreyer; Nikolaus Berndt; Johannes Eckstein; Michael Mülleder; Shabnam Hemmati-Sadeghi; Charlotte Klein; Basim Abuelnor; Alina Panzel; David Meierhofer; Joachim Spranger; Barbara Steiner; Sebastian Brachs
Journal:  Aging (Albany NY)       Date:  2021-04-16       Impact factor: 5.682

5.  Identification of key transcriptome biomarkers based on a vital gene module associated with pathological changes in Alzheimer's disease.

Authors:  Tong Zhang; Yang Shen; Yiqing Guo; Junyan Yao
Journal:  Aging (Albany NY)       Date:  2021-05-24       Impact factor: 5.682

6.  Subjective Experiences of Alzheimer's Disease in the Pakistani Cultural Context: An Exploratory Study.

Authors:  Amna Aurooj; Zahid Mahmood
Journal:  J Relig Health       Date:  2021-07-11

7.  Decreased Glucose Metabolism and Glutamine Synthesis in the Retina of a Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Anna Luna Mølgaard Tams; Berta Sanz-Morello; Emil Winther Westi; Zaynab Ahmad Mouhammad; Jens Velde Andersen; Kristine Karla Freude; Rupali Vohra; Jens Hannibal; Blanca Irene Aldana; Miriam Kolko
Journal:  Cell Mol Neurobiol       Date:  2021-07-14       Impact factor: 5.046

Review 8.  The Role of NCOA4-Mediated Ferritinophagy in Ferroptosis.

Authors:  Naiara Santana-Codina; Ajami Gikandi; Joseph D Mancias
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Thymosin β4 reverses phenotypic polarization of glial cells and cognitive impairment via negative regulation of NF-κB signaling axis in APP/PS1 mice.

Authors:  Meng Wang; Li-Rong Feng; Zi-Long Li; Kai-Ge Ma; Ke-Wei Chang; Xin-Lin Chen; Peng-Bo Yang; Sheng-Feng Ji; Yan-Bing Ma; Hua Han; John Bosco Ruganzua; Wei-Na Yang; Yi-Hua Qian
Journal:  J Neuroinflammation       Date:  2021-06-28       Impact factor: 8.322

10.  Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.

Authors:  Jeffrey Cummings
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2020-10-28       Impact factor: 2.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.